Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00572832 · ClinicalTrials.gov registry record · NA
Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting
A NA study of Human Papillomavirus Infection, sponsored by University of Pittsburgh.
- Completed
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT00572832 is a NA study of Human Papillomavirus Infection that has completed, run by University of Pittsburgh. The registered enrollment target is 200 participants, below the 1,307-participant average among 17 other Human Papillomavirus Infection trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00572832, a NA study of Human Papillomavirus Infection, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, open label trial of HPV (human papilloma virus) vaccine, comparing an on-time administration of the third dose with delayed administration of the third dose. All participants would receive the first and second doses according to schedule. They would be randomized to either vaccine at 6 months or vaccine at 12 months. Blood will be drawn for titers twice from all participants: pre-dose 1 and one month post third dose. We hypothesize that the GMTs in the test group (T) are non-inferior to the usual timing control group (C): H0: δ ≤ -δ0 versus H1: δ \> -δ0 where δ = log (GMTT )- log (GMTC) and δ0 is the pre-specified non-inferiority margin.
Conditions Studied
Interventions
- BIOLOGICAL Quadrivalent human papillomavirus vaccine on-time administration
- BIOLOGICAL Quadrivalent human papillomavirus vaccine delayed administration
Study Locations (1)
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00572832
The ClinicalTrials.gov registry entry for NCT00572832 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,307-participant average among 17 other Human Papillomavirus Infection trials with a reported enrollment target (85% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Human Papillomavirus Infection appearing as the primary indexed condition, and to 2 interventions - of which Quadrivalent human papillomavirus vaccine on-time administration is the first listed.
NCT00572832 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00572832 about?
NCT00572832 is a clinical study titled "Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting". This is a randomized, open label trial of HPV (human papilloma virus) vaccine, comparing an on-time administration of the third dose with delayed administration of the third dose. All participants would receive the first and second doses according to schedule. They would be randomized to either vacc...
What is the current status of trial NCT00572832?
This trial is currently completed. It is a NA study. The enrollment target is 200 participants. The study started on 2007-09. Estimated completion is 2009-08.
What conditions does trial NCT00572832 study?
This clinical trial studies the following conditions: Human Papillomavirus Infection.
What interventions are being tested in trial NCT00572832?
The interventions under investigation include: Quadrivalent human papillomavirus vaccine on-time administration (BIOLOGICAL), Quadrivalent human papillomavirus vaccine delayed administration (BIOLOGICAL).
Who is sponsoring clinical trial NCT00572832?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00572832 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papillomavirus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents
RECRUITING · NA
-
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)
RECRUITING · NA
-
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)
RECRUITING · NA
-
Feasibility Trial of a Multi-level Media Production and Social Marketing Campaign to Reduce HPV Vaccine Hesitancy
RECRUITING · NA
-
Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men
ACTIVE NOT RECRUITING · NA
-
Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) Asian/Asian American Women Supplement
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.